The co-administration of DOACs and inducers of P-gp and CYP3A4 may therefore reduce the bioavailability or increase the clearance of DOACs, with the potential to increase the risk of stroke and thromboembolism. The gene discussed is CYP3A4; the disease is stroke disorder.